Receiver in the canal (RIC) hearing aids for Hearing Aids

Phase-Based Progress Estimates
Hearing Aids+2 More
Receiver in the canal (RIC) hearing aids - Device
All Sexes
What conditions do you have?

Study Summary

This study is evaluating whether hearing aids may help reduce tinnitus for individuals with normal hearing.

Eligible Conditions
  • Hearing Aids
  • Normal Hearing
  • Tinnitus

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: The Tinnitus Functional index will be administered at baseline, 2-3 weeks after baseline, and 3 months after baseline

Month 3
Tinnitus Functional Index Change

Trial Safety

Trial Design

2 Treatment Groups

VA Clinician Interviews
1 of 2
Hearing Aid Study
1 of 2
Active Control
Experimental Treatment

35 Total Participants · 2 Treatment Groups

Primary Treatment: Receiver in the canal (RIC) hearing aids · No Placebo Group · N/A

Hearing Aid Study
Experimental Group · 1 Intervention: Receiver in the canal (RIC) hearing aids · Intervention Types: Device
VA Clinician InterviewsNoIntervention Group · 1 Intervention: VA Clinician Interviews · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: the tinnitus functional index will be administered at baseline, 2-3 weeks after baseline, and 3 months after baseline

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,472 Previous Clinical Trials
2,741,659 Total Patients Enrolled
Tara Zaugg, AuDPrincipal InvestigatorVA Portland Health Care System, Portland, OR

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have normal hearing at all frequencies between 25 Hz and 4 kHz as measured at the first study visit.
You have tinnitus and/or hearing loss.
You are capable of consenting and participating in a sexual activity.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: October 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
How old are they?
18 - 65100.0%
What site did they apply to?
VA Portland Health Care System, Portland, OR100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%